Mayo Clinic First in U.S. to Use Newly-Approved FDA Technology to Treat Atrial Fibrillation

ROCHESTER, Minn.--(BUSINESS WIRE)-- Mayo Clinic is the first in the U.S. to use the first minimally invasive freezing balloon technology for the treatment of atrial fibrillation (AF) approved in December by the U.S. Food and Drug Administration. The first patient received the treatment Tuesday, Jan. 4.

The technology is used to treat drug refractory recurrent symptomatic paroxysmal AF, a type of AF in which irregular heartbeats in the upper chambers of the heart start and stop suddenly on their own. The new system uses a balloon-based technology delivered through a catheter with a coolant rather than heat to create circumferential lesions around the pulmonary vein to block the conduction of AF in cardiac tissues. “This approach provides a single ablative means of eliminating problematic AF in patients who failed drug therapy,” says Douglas Packer, M.D., Mayo Clinic cardiologist.

Mayo Clinic was a trial site for STOP AF (Sustained Treatment of Paroxysmal Atrial Fibrillation), which led to FDA approval. The 26-site study involving 245 patients showed that 69.9 percent of patients treated with the balloon technology were free from AF at one year, compared with 7.3 percent of patients treated only with drug therapy, another method for treating AF. Dr. Packer was principal investigator of the clinical trial. “It is critical that these devices go through rigorous clinical trial testing to prove benefit and safety before they are approved,” he says.

Atrial fibrillation is the most common cardiac arrhythmia seen by physicians and affects more than 2 million Americans. Most individuals with atrial fibrillation have identifiable risk factors, such as high blood pressure or structural heart disease, and tend to be elderly. Long-term complications resulting from atrial fibrillation and its treatment can include death, disabling stroke, serious bleeding and/or cardiac arrest.

The new technology, the Arctic Front™ Cardiac CryoAblation Catheter system, is manufactured by Medtronic, based in Minneapolis.

About Mayo Clinic

Mayo Clinic is a non-profit worldwide leader in medical care, research and education for people from all walks of life. For more information, visit www.mayoclinic.com and www.mayoclinic.org/news.



CONTACT:

Mayo Clinic
Traci Klein
507-284-5005 (days)
507-284-2511 (evenings)
[email protected]
http://www.mayoclinic.org

KEYWORDS:   United States  North America  Minnesota

INDUSTRY KEYWORDS:   Health  Biotechnology  Cardiology  Hospitals  Medical Devices  FDA

MEDIA:

Logo
 Logo

Suggested Articles

Janssen’s BCMA-targeting CAR-T therapy eliminated tumors in 69% of patients with advanced multiple myeloma in a small phase 1 study.

In a study, BMS' CAR-T therapy banished tumors in more than half and shrank tumors in nearly three-quarters of relapsed blood cancer patients.

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.